JETEMA, Co., Ltd. (216080.KQ)
KRW 15130.0
(-2.64%)
KRW 15130.0
(-2.64%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 179.09 Billion KRW | 36.29% |
| 2022 | 131.4 Billion KRW | 40.75% |
| 2021 | 93.36 Billion KRW | 269.07% |
| 2020 | 25.29 Billion KRW | -10.77% |
| 2019 | 28.34 Billion KRW | -49.68% |
| 2018 | 56.33 Billion KRW | 271.07% |
| 2017 | 15.18 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 156.17 Billion KRW | -0.38% |
| 2024 Q1 | 156.77 Billion KRW | -12.46% |
| 2023 Q1 | 133.02 Billion KRW | 1.23% |
| 2023 FY | 179.09 Billion KRW | 36.29% |
| 2023 Q4 | 179.09 Billion KRW | 1.4% |
| 2023 Q3 | 176.61 Billion KRW | 26.5% |
| 2023 Q2 | 139.61 Billion KRW | 4.95% |
| 2022 Q4 | 131.4 Billion KRW | -4.56% |
| 2022 Q3 | 137.68 Billion KRW | 6.1% |
| 2022 Q2 | 129.76 Billion KRW | 46.64% |
| 2022 Q1 | 88.49 Billion KRW | -5.22% |
| 2022 FY | 131.4 Billion KRW | 40.75% |
| 2021 Q2 | 24.03 Billion KRW | 5.1% |
| 2021 Q4 | 93.36 Billion KRW | -12.33% |
| 2021 FY | 93.36 Billion KRW | 269.07% |
| 2021 Q1 | 22.87 Billion KRW | -9.58% |
| 2021 Q3 | 106.49 Billion KRW | 343.01% |
| 2020 Q1 | 18.42 Billion KRW | -28.22% |
| 2020 FY | 25.29 Billion KRW | -10.77% |
| 2020 Q3 | 26.93 Billion KRW | 11.73% |
| 2020 Q4 | 25.29 Billion KRW | -6.08% |
| 2020 Q2 | 24.1 Billion KRW | 30.83% |
| 2019 Q4 | 25.66 Billion KRW | 0.0% |
| 2019 FY | 28.34 Billion KRW | -49.68% |
| 2019 Q3 | - KRW | 0.0% |
| 2019 Q1 | - KRW | 0.0% |
| 2018 Q1 | - KRW | 0.0% |
| 2018 FY | 56.33 Billion KRW | 271.07% |
| 2017 FY | 15.18 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Co., Ltd. | 169.47 Billion KRW | -5.674% |
| iNtRON Biotechnology, Inc. | 1.88 Billion KRW | -9424.286% |
| BINEX Co., Ltd. | 75.68 Billion KRW | -136.624% |
| Bioneer Corporation | 80.61 Billion KRW | -122.169% |
| Anterogen.Co.,Ltd. | 19.98 Billion KRW | -796.049% |
| MEDIPOST Co., Ltd. | 135.73 Billion KRW | -31.941% |
| CrystalGenomics, Inc. | 97.82 Billion USD | -83.078% |
| Helixmith Co., Ltd | 73.55 Billion KRW | -143.471% |
| Chabiotech Co.,Ltd. | 1069.23 Billion KRW | 83.251% |
| Medy-Tox Inc. | 137.14 Billion KRW | -30.589% |
| Peptron, Inc. | 16.36 Billion KRW | -994.089% |
| Amicogen, Inc. | 248.12 Billion KRW | 27.822% |
| Genexine, Inc. | 79.68 Billion KRW | -124.754% |
| HLB Therapeutics Co.,Ltd. | 29.27 Billion KRW | -511.734% |
| LegoChem Biosciences, Inc. | 41.28 Billion KRW | -333.835% |
| ALTEOGEN Inc. | 108.25 Billion KRW | -65.429% |
| PharmaResearch Co., Ltd. | 73.08 Billion KRW | -145.04% |
| SillaJen, Inc. | 19.4 Billion KRW | -823.105% |
| OliX Pharmaceuticals,Inc | 52.48 Billion KRW | -241.197% |
| Genomictree Inc. | 7.81 Billion KRW | -2192.435% |
| MedPacto, Inc. | 9.56 Billion KRW | -1772.217% |
| D&D Pharmatech | 23.98 Billion KRW | -646.659% |
| EASY BIO,Inc. | 105.86 Billion KRW | -69.163% |
| GI Innovation, Inc. | 9.63 Billion KRW | -1758.524% |